GEG Tech Lenti-ONE™ are classical lentiviral vectors, derived from HIV-1 and deficient for replication. Lenti-ONE™ are integrative lentiviral vectors. They are produced with an integration proficient integrase, allowing their DNA genome to be stably integrated into the host cell chromatin. They thus allow robust and long term expression in dividing and non-dividing cells. Their tropism is defined by the envelop glycoprotein they have been produced with. GEG Tech offers Lenti-ONE™ pseudotyped with VSV glycoprotein, conferring a broad tropism, and Lenti-ONE™ pseudotyped with Mokola glycoprotein, conferring a glial specific tropism. Depending on your purpose and target cells, GEG Tech Lenti-ONE™ vectors are available at High Titer (108 TU/mL) and High Titer+ (109 TU/mL).
GEG Tech Lenti-ONE™ are integrative vectors. Hence, integration of the transgene with a suitable promoter allows robust and long term expression, even after cell divisions. Integration is expected to be favored in transcriptionally active regions of the chromatin and may induce genotoxicity such as deregulation of the transcriptome of transduced cells, potentially inducing immortalization of cells. GEG Tech proposes Lenti-ONE™ with a mutant integrase expected to display an integration profile closer to a random distribution and reduced genotoxicity. Lenti-ONE™ containing an IN(R166A) or an IN(Q168A) integrase mutant are hampered for interaction with LEDGF, a cellular factor, and yet retain integration capability.
Lenti-ONE™ are very flexible gene transfer tools and can transduce a large variety of cells. Lenti-ONE™ can mediate ubiquitous or cell specific expression depending on the envelope and the promoter selected for your vector. Indeed the envelope choice will determine the entry mechanism of the vector into the cell and the promoter choice will define the mechanism of transcription of the transgene. For example, the VSV envelope allows the entry of the Lenti-ONE™ vector in almost any mammalian cells and the CMV or PGK promoter induces ubiquitous expression of transgenes. Consequently, the combination of these elements generates ubiquitous Lenti-ONE™ capable of transducing and driving transgene expression in a wide range of cell types. In contrast, Mokola envelope restricts vector entry into glial cells, Lenti-ONE™ with this envelope will then preferentially transduce glial cells in vivo, in addition the GFAP promoter is expected to specifically drive expression in astrocytes. Consequently, the combined use of the Mokola envelope with a GFAP promoter will confer a high preference of Lenti-ONE™ particles for astrocytes. Depending on the experimental context, it is thus possible to combine a specific envelope with a specific promoter to control the specificity of expression.
Lenti-ONE™ can be used in large array of purposes. Taking advantage of Lenti-ONE™ features can significantly enhance your research. Here are some examples:
in vitro and in vivo applications: